Supplementary Fig. S2a shows that both CDK9 inhibitors suppressed the growth/viability of all the human AML lines, with MOLM13, which expresses an MLL-AF9 fusion, being especially sensitive. Here, KMT2A is linked to acute myeloid leukemia.